Filing Flows › Aclaris Therapeutics (ACRS) › How it makes money
How Aclaris Therapeutics (ACRS) makes money
Aclaris Therapeutics (ACRS) made $1.5M of revenue in the third quarter 2026 (Q3 2026), -55% from a year earlier. Licensing brought in $1.2M (80%); Contract research brought in $300K (20%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Licensing | $1.2M | 79.7% | -7% | -58% |
| Contract research | $300K | 20.3% | -16% | -38% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $1.5M | 100.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $1.5M | -55% |
| Q2 2026 | $1.6M | -8% |
From Aclaris Therapeutics' 10-Q filed Nov 5, 2026 (on EDGAR).
Questions
How does Aclaris Therapeutics make money?
Aclaris Therapeutics (ACRS) made $1.5M of revenue in the third quarter 2026 (Q3 2026), -55% from a year earlier. Licensing brought in $1.2M (80%); Contract research brought in $300K (20%).
What is Aclaris Therapeutics' biggest business?
Licensing: $1.2M in the third quarter 2026, 80% of revenue, -58% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.